|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Methods:</b> 100 consecutive patients with metastasized castration resistant prostate cancer (mCRPC) scheduled for PSMA-RLT were evaluated for prostate specific antigen (PSA), lactate dehydrogenase (LDH) and CgA at baseline and in follow-up of PSMA-RLT.
|
31653712 |
2019 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> MEDLINE, Embase, Web of Science, and Cochrane Library databases were searched to identify eligible studies published before September 2018, regarding the association of <i>CHGA</i> gene expression with survival outcomes in patients with PCa.
|
31114331 |
2019 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> MEDLINE, Embase, Web of Science, and Cochrane Library databases were searched to identify eligible studies published before September 2018, regarding the association of <i>CHGA</i> gene expression with survival outcomes in patients with PCa.
|
31114331 |
2019 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> We determined whether quantifying neuroblastoma-associated mRNAs (NB-mRNAs) in bone marrow and blood improves assessment of disease and prediction of disease progression in patients with relapsed/refractory neuroblastoma.<b>Experimental Design:</b> mRNA for CHGA, DCX, DDC, PHOX2B, and TH was quantified in bone marrow and blood from 101 patients concurrently with clinical disease evaluations.
|
28559462 |
2017 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> We determined whether quantifying neuroblastoma-associated mRNAs (NB-mRNAs) in bone marrow and blood improves assessment of disease and prediction of disease progression in patients with relapsed/refractory neuroblastoma.<b>Experimental Design:</b> mRNA for CHGA, DCX, DDC, PHOX2B, and TH was quantified in bone marrow and blood from 101 patients concurrently with clinical disease evaluations.
|
28559462 |
2017 |
|
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> We determined whether quantifying neuroblastoma-associated mRNAs (NB-mRNAs) in bone marrow and blood improves assessment of disease and prediction of disease progression in patients with relapsed/refractory neuroblastoma.<b>Experimental Design:</b> mRNA for CHGA, DCX, DDC, PHOX2B, and TH was quantified in bone marrow and blood from 101 patients concurrently with clinical disease evaluations.
|
28559462 |
2017 |
|
heart inflammation
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>In vivo</i> and <i>ex vivo</i> mechanistic studies showed that CgA can prevent Doxo-induced heart inflammation, oxidative stress, apoptosis, fibrosis, and ischemic injury.
|
30973759 |
2019 |
|
Senile Plaques
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>Rt</i> (10 <i>μ</i>g/ml) significantly inhibited the mean protein level of interleukin-1<i>β</i> (IL-1<i>β</i>) in the organotypic hippocampal slice cultures following treatment with chromogranin A (CGA, 10 nM) and pancreastatin (10 nM), endogenous microglial activators present in senile plaques.
|
29854069 |
2018 |
|
Familial (FPAH)
|
0.020 |
Biomarker
|
disease |
BEFREE |
(1) Plasma chromogranin A is a valuable (sensitive and specific) diagnostic tool in detecting both familial and sporadic pheochromocytoma.
|
2189303 |
1990 |
|
Neuroectodermal Tumor, Primitive
|
0.040 |
Biomarker
|
disease |
BEFREE |
1478 patients diagnosed with PNET in the National Cancer Database (2004-2014) were retrospectively identified, and logistic regression analyses were used to evaluate associations between the presence of metastatic disease and CgA level.
|
31239188 |
2020 |
|
Ewings sarcoma-primitive neuroectodermal tumor (PNET)
|
0.040 |
Biomarker
|
disease |
BEFREE |
1478 patients diagnosed with PNET in the National Cancer Database (2004-2014) were retrospectively identified, and logistic regression analyses were used to evaluate associations between the presence of metastatic disease and CgA level.
|
31239188 |
2020 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
23 patients were included.Estimated effects indicate that neuron-specific enolase (NSE) levels at baseline may be correlated with overall survival (NSE unit 18.3 ng/ml: HR1.262 (95% confidence interval (CI) 0.985-1.616)) and that chromogranin A (CGA) may be correlated with progression-free survival (CGA unit 98.1 ng/ml: HR1.341 (95% CI 1.011-1.778)). cfDNA analysis revealed mutations annotated in prostate cancer (PCA) and small cell cancers (SCC).
|
30286478 |
2018 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
23 patients were included.Estimated effects indicate that neuron-specific enolase (NSE) levels at baseline may be correlated with overall survival (NSE unit 18.3 ng/ml: HR1.262 (95% confidence interval (CI) 0.985-1.616)) and that chromogranin A (CGA) may be correlated with progression-free survival (CGA unit 98.1 ng/ml: HR1.341 (95% CI 1.011-1.778)). cfDNA analysis revealed mutations annotated in prostate cancer (PCA) and small cell cancers (SCC).
|
30286478 |
2018 |
|
Familial lichen amyloidosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
23 patients were included.Estimated effects indicate that neuron-specific enolase (NSE) levels at baseline may be correlated with overall survival (NSE unit 18.3 ng/ml: HR1.262 (95% confidence interval (CI) 0.985-1.616)) and that chromogranin A (CGA) may be correlated with progression-free survival (CGA unit 98.1 ng/ml: HR1.341 (95% CI 1.011-1.778)). cfDNA analysis revealed mutations annotated in prostate cancer (PCA) and small cell cancers (SCC).
|
30286478 |
2018 |
|
Malignant Carcinoid Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
5-HIAA = 5-hydroxyindoleacetic acid; CgA = chromogranin A; CI = confidence interval; CLARINET = Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors; CS = carcinoid syndrome; ELECT = Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment; HR = hazard ratio; ITT = intention-to-treat; NET = neuroendocrine tumor; PanNET = pancreatic NET; PFS = progression-free survival; PPI = proton pump inhibitor; SSA = somatostatin analogue; ULN = upper limit of normal.
|
30084687 |
2018 |
|
Well Differentiated Pancreatic Endocrine Tumor
|
0.060 |
Biomarker
|
disease |
BEFREE |
5-HIAA = 5-hydroxyindoleacetic acid; CgA = chromogranin A; CI = confidence interval; CLARINET = Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors; CS = carcinoid syndrome; ELECT = Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment; HR = hazard ratio; ITT = intention-to-treat; NET = neuroendocrine tumor; PanNET = pancreatic NET; PFS = progression-free survival; PPI = proton pump inhibitor; SSA = somatostatin analogue; ULN = upper limit of normal.
|
30084687 |
2018 |
|
Endocrine Gland Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
5-HIAAA = 5-hydroxyindoleacetic acid; 5-HTP = 5-hydroxytryptophan; CGA = chromogranin A; ETM = endocrine tumor marker; MTC = medullary thyroid carcinoma; UHLETM = unexpectedly high level of endocrine tumor marker.
|
30106635 |
2018 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
SCLC (H146, H345) and carcinoid (H727) cell lines express neuroendocrine cell markers, including chromogranin A, neural cell adhesion molecule (N-CAM), 5HT, and tryptophan hydroxylase.
|
12397014 |
2002 |
|
Pineal Gland Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pineal parenchymal tumor (PPT) differentiation was confirmed by immunohistochemical detection of neuroendocrine markers (synaptophysin, neurofilaments, and chromogranin A).
|
12701886 |
2003 |
|
Gastrointestinal Stromal Tumors
|
0.010 |
AlteredExpression
|
group |
BEFREE |
GISTs share similar expression patterns with Type III/IV GCs but have decreased CgA.MTA1 is a marker of tumor invasion.
|
16502410 |
2006 |
|
Medullary carcinoma of thyroid
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Medullary thyroid cancer (MTC) cells characteristically express the transcription factor ASCL1 (achaete-scute complex-like 1) as well as high levels of the neuroendocrine (NE) markers calcitonin and chromogranin A (CgA).
|
17090547 |
2006 |
|
Prolactinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Prolactinomas (5/5) did not express chromogranin A mRNA or protein, but contained chromogranin B mRNA.
|
2709813 |
1989 |
|
Pituitary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Pituitary tumors expressed chromogranin A and closely resembled human pituitary adenomas.
|
27769070 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor marker response (5-hydroxyindoleacetic acid [n = 7] and chromogranin A [n = 13]) at 3 months after treatment were as follows: none (n = 0, 4), partial (n = 6, 7), and complete (n = 1, 2).
|
28132407 |
2017 |
|
Progressive Neoplastic Disease
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Progressive disease could be identified and surgical resection verified.Chromogranin A had no clinical utility.
|
29145657 |
2018 |